By Finance Pulse in KeyInfo —

Novo Nordisk's CagriSema Achieves 22.7% Weight Loss

Novo Nordisk's experimental drug CagriSema shows promise with 22.7% weight loss in patients, approaching the anticipated 25%. Discover the latest in weight-loss research.

A sleek and modern design featuring a stylized depiction of a weighing scale, with subtle progress b
Novo Nordisk's CagriSema Achieves 22.7% Weight Loss

Novo Nordisk's experimental drug, CagriSema, helped patients reduce 22.7% of their weight, short of the anticipated 25%.

Source